News / Taiwan / economic_daily
TaiMed Biologics Reports 287% Revenue Surge, Targeting 2027 Profitability
Health Technology · Biotechnology · economic_daily · 2026-11-08
6589
TaiMed Biologics saw October revenue jump 287.8% year-over-year, driven by its dual-engine strategy of CDMO services and biosimilar development.
What Happened
Revenue Performance: TaiMed Biologics reported October revenue exceeding NT$270 million, a 287.8% year-over-year increase. Cumulative revenue for the first ten months reached NT$1.4 billion, marking a three-year high driven by CDMO expansion and international licensing milestones.
Regulatory Progress: The biosimilar EG1206A has been submitted for European regulatory approval, with filings for the US FDA and Canada expected by year-end. The company plans to launch in Europe by 2027 and the US by 2028, anticipating revenue from profit-sharing agreements.
Dual-Engine Strategy: TaiMed continues to leverage its CDMO and biosimilar development strategy. Its Zhubei plant is currently undergoing inspection by Japan's PMDA, with the goal of shipping commercial products to Japanese clients starting in 2027.
Future Outlook: Chairman Liu Li-cheng stated that the company expects significant improvements in its operational scale and profit structure by the second half of 2027. The company aims to transition into a global commercialization phase through ongoing product development and international partnerships.